Succinic Acid

Succinic Acid

SCHEMBL508133

CC(=O)c1cccc(CNc2c(Cl)ccc3c2CCNCC3)c1.O=C(O)CCC(=O)O

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4

The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRM3 known ✓ P20309 1/20 0.38
HTR2A known ✓ P28223 1/20 0.36
HTR2C known ✓ P28335 1/20 0.36
WDR5 P61964 5/20 0.39
MRGPRX4 Q96LA9 2/20 0.38
ITGB3 P05106 1/20 0.38
ITGA2 P17301 1/20 0.38
ROCK2 O75116 4/20 0.37
PRKG1 Q13976 2/20 0.37
PKN2 Q16513 2/20 0.36
PRKCE Q02156 1/20 0.36
HTR2B P41595 3/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
FFAR1 O14842 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10228051 0.95 WDR5 (0.42) WDR5MRGPRX4CHRM3ROCK2PRKG1
Succinic Acid SCHEMBL507040 0.88 HTR2A (0.39) HTR2BHTR2AHTR2CFFAR1
Succinic Acid SCHEMBL10476256 0.88 KMT2A (0.41) WDR5MRGPRX4HTR2BHTR2AHTR2C
Succinic Acid SCHEMBL507160 0.86 FFAR1 (0.46) CHRM3HTR2BHTR2AHTR2CFFAR1
Succinic Acid SCHEMBL10476157 0.86 FFAR1 (0.37) WDR5HTR2BHTR2AHTR2CFFAR1
Succinic Acid SCHEMBL10476225 0.86 MAPT (0.43)
Succinic Acid SCHEMBL506477 0.83 HTR2A (0.38) ITGB3ITGA2HTR2BHTR2AHTR2C
SCHEMBL11947457 0.83 CHRM3 (0.40) WDR5CHRM3ROCK2PRKG1PKN2
SCHEMBL506785 0.82 HTR2A (0.43) HTR2BHTR2AHTR2C
Succinic Acid SCHEMBL507210 0.82 FFAR1 (0.47) MRGPRX4HTR2BHTR2AHTR2CFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720836-B1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2014-04-16 EP disclosed
US-8580780-B2 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist ELI LILLY AND COMPANY (US) 2013-11-12 US disclosed
EP-2479168-A1 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists ELI LILLY AND COMPANY (US) 2012-07-25 EP disclosed
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 US disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 CHRM3 669/4885HTR2A 4/4885HTR2C 1/4885
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A CHRM3 569/4885HTR2A 4/4885HTR2C 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.